potentially important times, page-18

With apologies to Worthind, who was right on the money, there is a meeting coming up with the FDA. The meeting is for a number of things - only some of which I know. One is the possibility of getting ATC to market more quickly by reducing the number of patients needed. Of further interest, the trial is unblinded to the FDA but still blinded to Avexa. The FDA has all the trial data provided to the Drug Monitoring Safety Board (DMSB) and by the time of the meeting (probably already) the FDA will have the DSMB's full recommendations and report. Again, credit to Worthind on this. Not sure when the meeting is.